Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer

Ezra Cohen, MD
Published: Friday, Sep 22, 2017



Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

The KEYNOTE-040 trial evaluated pembrolizumab (Keytruda) versus standard of care in patients with recurrent or metatstaic head and neck squamous cell carcinoma.

This was the first effort in a randomized setting to demonstrate benefit, though statistically, it did not meet its endpoint.
 
SELECTED
LANGUAGE


Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

The KEYNOTE-040 trial evaluated pembrolizumab (Keytruda) versus standard of care in patients with recurrent or metatstaic head and neck squamous cell carcinoma.

This was the first effort in a randomized setting to demonstrate benefit, though statistically, it did not meet its endpoint.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x